Preclinical Evaluation of Eltrombopag in a PDX Model of Myelodysplastic Syndromes

Investigators demonstrated that their robust, patient-derived xenograft (PDX) model for myelodysplastic syndrome was applicable as a preclinical platform to address pending clinical questions by interrogating the efficacy and safety of the thrombopoietin receptor agonist eltrombopag.